TEQCool AB (“TEQcool” or the “Company”) reports on progress in its product development as well as in positioning the Company and its technology on the market.
Driving Progress and Innovation at TEQCool
TEQCool continues to make significant strides in the development of the world’s most targeted Brain Cooling system. With focused efforts on key milestones and valuable insights from leading clinicians, the journey toward innovation is moving forward with great momentum.
Over the past few months, the team has achieved critical project advancements. A significant milestone has been the successful completion of the Design Input Review, ensuring that the product aligns with stringent clinical and regulatory requirements. Additionally, the project plan has been further refined, providing a streamlined roadmap that enhances efficiency, innovation, and quality.
Looking Ahead!
Our strategic approach has been to ensure the project remains on track and meets key objectives efficiently. Collaboration with top-tier medical experts has played a crucial role in refining the system. Each of these collaborations continues to reaffirm that TEQCool is addressing a critical unmet need in neurocritical care. The ability to integrate their feedback quickly into the development process provides a competitive advantage in reducing time to market.
TEQCool remains committed to continued engagement with surgeons and clinicians to integrate their invaluable feedback into the development process. The goal is not just to innovate but to create a solution that is both transformative and seamlessly applicable in medical practice. Together, a groundbreaking technology is being built—one that will not only save lives but also set a new standard in neurocritical care.
An Exciting development journey lies ahead, and more updates will be shared in the coming months. TEQCool thanks all supporters for their continued belief in this mission as the company advances toward delivering a revolutionary product.
Sincerely,
TEQCool Team
For further information regarding TEQCool, please contact:
Anders Sjögren, CEO TEQCool AB, E-mail: ir@teqcool.com
About Us
TEQCool AB is a medical technology company in Lund, Sweden. TEQCool is developing a unique, patented solution for selective cooling of the brain in patients at risk of oxygen deprivation. The company is initially targeting patients with severe brain damage who suffer from neurological fever, but the need exists in many areas, such as heart attack, stroke, blood poisoning, COVID and other serious viral diseases, neonatal, suicide attempts, etc. The intended therapy is based on many years of research and development at Lund University, as well as preclinical and clinical studies.
Attachments
Innovating the Future of Neurocritical Care